These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 422706)

  • 1. Metabolic clearance and plasma half-disappearance time of exogenous somatostatin in man.
    Sheppard M; Shapiro B; Pimstone B; Kronheim S; Berelowitz M; Gregory M
    J Clin Endocrinol Metab; 1979 Jan; 48(1):50-3. PubMed ID: 422706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic clearance and plasma half disappearance time of exogenous gonadotropin releasing hormone in normal subjects and in patients with liver disease and chronic renal failure.
    Pimstone B; Epstein S; Hamilton SM; LeRoith D; Hendricks S
    J Clin Endocrinol Metab; 1977 Feb; 44(2):356-60. PubMed ID: 320223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disappearance rates of plasma growth hormone after intravenous somatostatin in renal and liver disease.
    Pimstone BL; Le Roith D; Epstein S; Kronheim S
    J Clin Endocrinol Metab; 1975 Aug; 41(2):392-3. PubMed ID: 1159052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic clearance rate of biosynthetic growth hormone after endogenous growth hormone suppression with a somatostatin analogue in chronic renal failure patients and control subjects.
    García-Mayor RV; Pérez AJ; Gandara A; Andrade A; Mallo F; Casanueva FF
    Clin Endocrinol (Oxf); 1993 Sep; 39(3):337-43. PubMed ID: 8222296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism of neurotensin and pancreatic polypeptide in man: role of the kidney and plasma factors.
    Shulkes A; Bijaphala S; Dawborn JK; Fletcher DR; Hardy KJ
    J Clin Endocrinol Metab; 1984 May; 58(5):873-9. PubMed ID: 6707191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic clearance of recombinant human growth hormone in health and chronic renal failure.
    Haffner D; Schaefer F; Girard J; Ritz E; Mehls O
    J Clin Invest; 1994 Mar; 93(3):1163-71. PubMed ID: 8132756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal clearance, metabolic clearance rate, and half-life of human growth hormone in young and aged subjects.
    Sohmiya M; Kato Y
    J Clin Endocrinol Metab; 1992 Dec; 75(6):1487-90. PubMed ID: 1464653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure.
    Kawai S; Ichikawa Y; Homma M
    J Clin Endocrinol Metab; 1985 May; 60(5):848-54. PubMed ID: 3980669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in vivo metabolism of somatostatin 28: possible relationship between diminished metabolism and enhanced biological action.
    Polonsky K; Jaspan J; Berelowitz M; Pugh W; Moossa A; Ling N
    Endocrinology; 1982 Nov; 111(5):1698-703. PubMed ID: 6127205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin and serum gastrin in normal subjects and in patients with pernicious anaemia, chronic liver and renal disease.
    Le Roith D; Vinik AI; Epstein S; Baron P; Olkenitzky MN; Pimstone BL
    S Afr Med J; 1975 Sep; 49(39):1601-4. PubMed ID: 1179234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic clearance and plasma half-disappearance time of D-TRP6 and exogenous luteinizing hormone-releasing hormone.
    Barron JL; Millar RP; Searle D
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1169-73. PubMed ID: 6210706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and effects of intravenous infusion of somatostatin in normal subjects--a two-compartment open model.
    Ho LT; Chen RL; Chou TY; Fong JC; Wang PS; Chou CK
    Clin Physiol Biochem; 1986; 4(4):257-67. PubMed ID: 2875821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Marked prolongation in disappearance half-time of plasma cholecystokinin-octapeptide in patients with hepatic cirrhosis.
    Kanayama S; Himeno S; Kurokawa M; Shinomura Y; Kuroshima T; Okuno M; Tsuji K; Higashimoto Y; Ikei N; Hashimura E
    Am J Gastroenterol; 1985 Jul; 80(7):557-60. PubMed ID: 4014106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma half disappearance time and metabolic clearance rate of exogenous LH-RH in patients with chronic renal failure.
    Gryczyńska M; Kosowicz J; Czekalski S
    Mater Med Pol; 1980; 12(1-2):124-8. PubMed ID: 7035762
    [No Abstract]   [Full Text] [Related]  

  • 15. Glucagon metabolism in man, studies on the metabolic clearance rate and the plasma acute disappearance time of glucagon in normal and diabetic subjects.
    Alford FP; Bloom SR; Nabarro JD
    J Clin Endocrinol Metab; 1976 May; 42(5):830-8. PubMed ID: 773949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of elevated serum pancreatic polypeptide concentrations in chronic renal failure.
    Lamers CB; Diemel CM; van Leer E; van Leusen R; Peetoom JJ
    J Clin Endocrinol Metab; 1982 Nov; 55(5):922-6. PubMed ID: 6126488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man.
    Nicholson WE; DeCherney GS; Jackson RV; DeBold CR; Uderman H; Alexander AN; Rivier J; Vale W; Orth DN
    J Clin Endocrinol Metab; 1983 Dec; 57(6):1263-9. PubMed ID: 6313734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms.
    Burgon PG; Stanton PG; Robertson DM
    Endocrinology; 1996 Nov; 137(11):4827-36. PubMed ID: 8895353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal contribution to increased clearance of exogenous growth hormone in obese hypertensive patients.
    Buijs MM; de Leeuw PW; Houben AJ; Kroon AA; Frölich M; Pijl H; Meinders AE
    J Clin Endocrinol Metab; 2005 Feb; 90(2):795-9. PubMed ID: 15572427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.